April 16, 2014 6:25 PM ET

Biotechnology

Company Overview of CSL Behring UK Limited

Company Overview

CSL Behring UK Limited engages in the research, development, manufacture, and marketing of plasma-derived and recombinant therapies worldwide. Its therapies are used for the treatment of various serious and rare conditions, such as coagulation (bleeding) disorders that include haemophilia and von Willebrand disease, as well as immune deficiencies; reversal of warfarin; and prevention of haemolytic disease in newborns resulting from Rh factor incompatibilities. The company’s research and development programs are focused in areas, such as plasma replacement therapies, vaccines, ISCOMATRIX adjuvant, and therapeutic proteins. CSL Behring UK Limited was formerly known as ZLB Behring UK Ltd. and c...

Hayworth House

Market Place

Haywards Heath,  RH16 1DB

United Kingdom

Founded in 1982

Phone:

44 1444 447 402

Fax:

44 1444 447 403

Key Executives for CSL Behring UK Limited

Senior Vice President of Research and Development
Director of Public Relations
Vice President of Research and Development
Compensation as of Fiscal Year 2013.

CSL Behring UK Limited Key Developments

European Medicines Agency Approves Once Every Two Weeks Dosing Option For Hizentra(R) (Human Normal Immunoglobulin, SCIg)

CSL Behring UK Ltd. announced that the European Medicines Agency (EMA) has expanded the administration options for Hizentra(R), human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly). Hizentra initially received EMA approval in 2011 as a 20%, once weekly SCIg replacement therapy for adults and children with PID to help treat existing or chronic infections and prevent new infections from occurring. Hizentra can also be stored at room temperature for up to 30 months meaning it is ready to use. Dosing once every two weeks with Hizentra can offer adult and paediatric patients consistent levels of IgG similar to weekly infusions, while providing patients with the option of infusing less frequently. The data to support dosing once every two weeks with Hizentra is based on the principles of pharmacometrics and pharmacokinetic modelling that included 3,800 data points for U.S. and EU clinical trials and 300 simulated trials. Hizentra is indicated for: Replacement therapy in adults and children in primary immunodeficiency (PID) syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiency; IgG subclass deficiencies with recurrent infections; Replacement therapy in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

Similar Private Companies By Industry

Company Name Region
nanoTherics Limited Europe
Arrow Therapeutics, Ltd. Europe
Dundee Cell Products Ltd. Europe
WGP 1 Plc Europe
Atazoa Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL Behring UK Limited, please visit www.cslbehring.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.